Iheezo is a small molecule that works as a Sodium Channel Alpha Subunit Blocker.[2] It is being used across 4 indications, with its most advanced program in Approved.[1]
Iheezo is one of 86 small molecule programs targeting Pain. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
275 competitors in Total Knee Arthroplasty
Iheezo
Lyrica
Xarelto
Sufenta
Xylocaine
Nucynta
Epsom Salt
Zanaflex
Nexium
Botox
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
NESACAINE
NDA NDA009435
Sep 26, 2017
CLOROTEKAL
NDA NDA208791
Sep 27, 2022
IHEEZO
NDA NDA216227
Sources
Details